ID   NCI-H324
AC   CVCL_3953
SY   H324; H-324
DR   BTO; BTO:0003005
DR   cancercelllines; CVCL_3953
DR   Cosmic; 844594
DR   Cosmic; 877238
DR   Cosmic; 877406
DR   Cosmic; 903572
DR   Cosmic; 1152501
DR   Cosmic; 1891885
DR   GEO; GSM794283
DR   IARC_TP53; 517
DR   Wikidata; Q54908035
RX   PubMed=1311061;
RX   PubMed=3335022;
RX   PubMed=3940644;
RX   PubMed=6148444;
RX   PubMed=8806092;
RX   PubMed=20679594;
RX   PubMed=28196595;
RX   PubMed=29681454;
RX   PubMed=31803961;
WW   https://tcpaportal.org/mclp/
CC   Part of: MD Anderson Cell Lines Project.
CC   Population: African American.
CC   Doubling time: 47 hours (Note=In RPMI 1640 + 10% FBS), 122 hours (Note=In ACL-3 + BSA) (PubMed=3940644).
CC   Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg249Ser (c.747G>C); ClinVar=VCV000406598; Zygosity=Unspecified (PubMed=1311061).
CC   Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Asp259Val (c.776A>T); ClinVar=VCV000485034; Zygosity=Unspecified (PubMed=1311061).
CC   Omics: Deep exome analysis.
CC   Omics: Protein expression by reverse-phase protein arrays.
CC   Omics: SNP array analysis.
CC   Omics: Transcriptome analysis by microarray.
CC   Omics: Transcriptome analysis by RNAseq.
CC   Derived from site: Metastatic; Pleural effusion; UBERON=UBERON_0000175.
ST   Source(s): PubMed=20679594
ST   Amelogenin: X,Y
ST   CSF1PO: 11,12
ST   D13S317: 11,12
ST   D16S539: 9
ST   D5S818: 11,12
ST   D7S820: 11,12
ST   TH01: 6
ST   TPOX: 8,9
ST   vWA: 17,18
DI   NCIt; C3512; Lung adenocarcinoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
SX   Male
AG   63Y
CA   Cancer cell line
DT   Created: 04-04-12; Last updated: 05-10-23; Version: 22
//
RX   PubMed=1311061;
RA   Mitsudomi T., Steinberg S.M., Nau M.M., Carbone D.P., D'Amico D.,
RA   Bodner S.M., Oie H.K., Linnoila R.I., Mulshine J.L., Minna J.D.,
RA   Gazdar A.F.;
RT   "p53 gene mutations in non-small-cell lung cancer cell lines and their
RT   correlation with the presence of ras mutations and clinical
RT   features.";
RL   Oncogene 7:171-180(1992).
//
RX   PubMed=3335022;
RA   Alley M.C., Scudiero D.A., Monks A., Hursey M.L., Czerwinski M.J.,
RA   Fine D.L., Abbott B.J., Mayo J.G., Shoemaker R.H., Boyd M.R.;
RT   "Feasibility of drug screening with panels of human tumor cell lines
RT   using a microculture tetrazolium assay.";
RL   Cancer Res. 48:589-601(1988).
//
RX   PubMed=3940644;
RA   Brower M., Carney D.N., Oie H.K., Gazdar A.F., Minna J.D.;
RT   "Growth of cell lines and clinical specimens of human non-small cell
RT   lung cancer in a serum-free defined medium.";
RL   Cancer Res. 46:798-806(1986).
//
RX   PubMed=6148444; DOI=10.1093/jnci/73.4.801;
RA   Morstyn G., Russo A., Carney D.N., Karawya E., Wilson S.H. Jr.,
RA   Mitchell J.B.;
RT   "Heterogeneity in the radiation survival curves and biochemical
RT   properties of human lung cancer cell lines.";
RL   J. Natl. Cancer Inst. 73:801-807(1984).
//
RX   PubMed=8806092; DOI=10.1002/jcb.240630505;
RA   Phelps R.M., Johnson B.E., Ihde D.C., Gazdar A.F., Carbone D.P.,
RA   McClintock P.R., Linnoila R.I., Matthews M.J., Bunn P.A. Jr.,
RA   Carney D.N., Minna J.D., Mulshine J.L.;
RT   "NCI-Navy Medical Oncology Branch cell line data base.";
RL   J. Cell. Biochem. 63 Suppl. 24:32-91(1996).
//
RX   PubMed=20679594; DOI=10.1093/jnci/djq279;
RA   Gazdar A.F., Girard L., Lockwood W.W., Lam W.L., Minna J.D.;
RT   "Lung cancer cell lines as tools for biomedical discovery and
RT   research.";
RL   J. Natl. Cancer Inst. 102:1310-1321(2010).
//
RX   PubMed=28196595; DOI=10.1016/j.ccell.2017.01.005;
RA   Li J., Zhao W., Akbani R., Liu W.-B., Ju Z.-L., Ling S.-Y., Vellano C.P.,
RA   Roebuck P., Yu Q.-H., Eterovic A.K., Byers L.A., Davies M.A., Deng W.-L.,
RA   Gopal Y.N.V., Chen G., von Euw E.M., Slamon D.J., Conklin D.,
RA   Heymach J.V., Gazdar A.F., Minna J.D., Myers J.N., Lu Y.-L., Mills G.B.,
RA   Liang H.;
RT   "Characterization of human cancer cell lines by reverse-phase protein
RT   arrays.";
RL   Cancer Cell 31:225-239(2017).
//
RX   PubMed=29681454; DOI=10.1016/j.cell.2018.03.028;
RA   McMillan E.A., Ryu M.-J., Diep C.H., Mendiratta S., Clemenceau J.R.,
RA   Vaden R.M., Kim J.-H., Motoyaji T., Covington K.R., Peyton M.,
RA   Huffman K., Wu X.-F., Girard L., Sung Y., Chen P.-H., Mallipeddi P.L.,
RA   Lee J.Y., Hanson J., Voruganti S., Yu Y., Park S., Sudderth J.,
RA   DeSevo C., Muzny D.M., Doddapaneni H., Gazdar A.F., Gibbs R.A.,
RA   Hwang T.H., Heymach J.V., Wistuba I.I., Coombes K.R., Williams N.S.,
RA   Wheeler D.A., MacMillan J.B., DeBerardinis R.J., Roth M.G.,
RA   Posner B.A., Minna J.D., Kim H.S., White M.A.;
RT   "Chemistry-first approach for nomination of personalized treatment in
RT   lung cancer.";
RL   Cell 173:864-878.e29(2018).
//
RX   PubMed=31803961; DOI=10.1002/jcb.29564;
RA   Mulshine J.L., Ujhazy P., Antman M., Burgess C.M., Kuzmin I.A.,
RA   Bunn P.A. Jr., Johnson B.E., Roth J.A., Pass H.I., Ross S.M.,
RA   Aldige C.R., Wistuba I.I., Minna J.D.;
RT   "From clinical specimens to human cancer preclinical models -- a journey
RT   the NCI-cell line database-25 years later.";
RL   J. Cell. Biochem. 121:3986-3999(2020).
//